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ABSTRACT - Purpose. Histone modification has emerged as a promising approach to cancer therapy. The short-
chain fatty acid, butyric acid, a histone deacetylase (HD) inhibitor, has shown anticancer activity. Butyrate 
transcriptional activation is indeed able to withdraw cancer cells from the cell cycle, leading to programmed cell 
death. Since butyrate’s clinical use is hampered by unfavorable pharmacokinetic and pharmacodynamic 
properties, delivery systems, such as solid lipid nanoparticles (SLN), have been developed to overcome these 
constraints. Methods. In order to outline the influence of butyrate delivery on its anticancer activity, the effects 
of butyrate as a free (sodium butyrate, NB) or nanoparticle (cholesteryl butyrate solid lipid nanoparticles, CBSLN) 
formulation on the growth of different human cancer cell lines, such as the promyelocytic leukemia, HL-60, and 
the breast cancer, MCF-7 was investigated. A detailed investigation into the mechanism of the induced 
cytotoxicity was also carried out, with a special focus on the modulation of HD and cyclin-dependent kinase 
(CDK) mRNA gene expression by real time PCR analysis. Results. In HL-60 cells, CBSLN induced a higher and 
prolonged expression level of the butyrate target genes at lower concentrations than NB. This led to a significant 
decrease in cell proliferation, along with considerable apoptosis, cell cycle block in the G0/G1 phase, significant 
inhibition of total HD activity and overexpression of the p21 protein. Conversely, in MCF-7 cells, CBSLN did 
not enhance the level of expression of the butyrate target genes, leading to the same anticancer activity as that of 
NB. Conclusions. Solid lipid nanoparticles were able to improve butyrate anticancer activity in HL-60, but not in 
MCF-7 cells. This is consistent with difference in properties of the cells under study, such as expression of the 
TP53 tumor suppressor, or the transporter for short-chain fatty acids, SLC5A8. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_________________________________________________________________________________ 
 
INTRODUCTION 
 
Butyric acid is the main short-chain fatty acid 
(SCFA) produced by bacterial fermentation of 
dietary fiber in the colon. It is well known that 
butyrate plays an important role in the homeostasis 
of colonic mucosa by inducing pathways for cell 
maturation, as well as cell cycle arrest, 
differentiation and apoptosis (1). Butyrate-mediated 
regulation of apoptotic pathways also occurs in 
cancer cells, including myeloid leukemia and breast 
cancer cells, and is not limited to the gastrointestinal 
tract (2-4). Transcription is the primary target of 
butyrate, since it causes histone hyperacetylation 
through non-competitive and reversible inhibition of 
histone deacetylase (HD). 
 
Butyrate enables DNA binding of several 
transcription factors, leading to higher genomic 
activity (5, 6). Apoptosis induced by histone 
deacetylase inhibitors (HDI) is generally associated 
with various disarrays of cell signaling pathways (7). 
Indeed, various studies have demonstrated the 
importance of epigenetic alteration, leading to gene 
silencing or abnormal expression as a cancer 
hallmark, and have proposed ‘epigenetic’ therapies 
capable of controlling transcription, as a promising 
approach in cancer therapeutics (8-10). The efficacy 
of HDI in cancer therapy may well stem from their 
restoration of silenced gene expression.  
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One such example is the fact that the powerful tumor 
suppressor p53 is the most commonly inactivated 
protein in human tumors (11). Its inactivation may 
be the result of TP53 gene alterations and 
approximately 50% of human cancers carry 
mutations in this gene (12). 
It has now been well established that HDI 
treatment induces the expression of the cyclin-
dependent kinase (CDK) inhibitor, p21. This plays a 
critical role in the regulation of cell cycle arrest and 
apoptosis, causing G1 arrest (13-16). HDIs have also 
been shown to induce p16 (CDKN2 or INK4) and 
p27, but they attenuate levels of cyclin A and cyclin 
D, leading to decreased CDK4 and CDK2 activity 
(17). HDI treatment triggers both the intrinsic 
pathway and sensitizes tumor cells to the extrinsic 
death ligand-induced pathway of apoptosis (17, 18). 
HDIs also have non-histone substrates and can 
modulate transcription by directly 
acetylating/deacetylating transcription factors, as 
well as associated cofactors such as Sp1 transcription 
factors or proteins, including p53 (19). Butyric acid 
seems to be particularly selective in regulating gene 
expression, leading to transcriptional activation of 
certain genes, such as CDKN1A coding p21 in a p53-
independent manner (20, 21). However, although the 
precise molecular mechanism involved in the cancer 
therapeutics of butyric acid has not yet been fully 
clarified, it does seem to be highly dependent on the 
cellular context. 
The clinical use of butyrate as an anticancer 
agent is hampered by unfavorable pharmacokinetic 
and pharmacodynamic properties. These include its 
short half-life, which requires administration of 
continuous parenteral infusions to maintain 
therapeutic concentrations (22, 23). By extension, 
factors affecting intracellular accumulation of 
butyrate could potentially influence its availability to 
modulate gene expression and, hence, processes 
such as proliferation, differentiation and apoptosis 
(24). Although free diffusion of fatty acids may take 
place, it has very little physiological relevance in the 
uptake of butyrate. There is now a considerable body 
of evidence suggesting that SCFAs are 
predominantly taken up via a facilitated process 
involving a number of transport proteins. 
The relatively recent characterization of a 
number of trans-membrane proteins has led to two 
well-defined routes of uptake, both monocarboxylate 
transport proteins: MCT1 also known as SLC16A1, 
a hydrogen coupled transporter, and SMCT1 
(SLC5A8), a sodium-coupled transporter (25). Thus, 
varying levels of transporter expression may result in 
a varied cellular uptake of butyrate. In particular, 
SLC5A8 is the first plasma membrane transporter 
postulated to function as a tumor suppressor (26). 
Silencing of its expression by epigenetic 
mechanisms is an early event in the progression of 
colorectal cancer and re-expression of the gene in 
colon tumor cell lines induces apoptosis and prevents 
colony formation (27, 28). 
The newly developing field of nanomedicine 
offers very promising applications for 
nanotechnology as a drug delivery platform. The aim 
of nanomedicine can be broadly defined as the 
comprehensive monitoring, control, construction, 
repair, defense and improvement of all human 
biological systems, working from the molecular 
level using engineered devices and nanostructures, 
ultimately to achieve medical benefits. Thanks to 
their small size, nanoparticulate drug delivery 
systems are encouraging goals in cancer therapy 
approaches. These include selective or targeted drug 
delivery, enhanced drug transport across biological 
barriers (leading to an increased bioavailability of 
the entrapped drug) or intracellular drug delivery, 
which minimizes systemic side effects and improves 
the solubility of poorly water-soluble drugs (29). 
Thus, cholesteryl butyrate solid lipid nanoparticles 
(CBSLN) have been put forward as a special delivery 
system to improve butyrate anticancer activity. This 
is because they are also a pro-drug, with the lipid 
matrix of solid lipid nanoparticles made up of 
cholesteryl butyrate i.e. the ester of cholesterol and 
butyric acid (30, 32). Previous studies have shown 
that CBSLN are able to prevent premature 
degradation of the incorporated butyrate and 
enhance cell membrane crossing (including the 
blood-brain barrier) (33), oral bioavailability and 
anticancer efficacy (31, 34-36). Moreover, CBSLN 
have shown very low systemic toxicity (37, 38) as 
their matrix contains physiological components 
and/or excipients of accepted status (FDA-approved 
constituents) (39, 40). Thus, CBSLN as a butyrate 
drug delivery system might be a valuable anticancer 
tool, since it improves several aspects of butyrate 
pharmacology. However, to date, there have been no 
reports on the effects of CBSLN on butyrate 
anticancer activity at molecular level. 
Our aim was to investigate the anticancer 
activity of butyric acid as a lipid nanoparticle 
formulation, with special attention to mRNA gene 
expression modulation in different human cancer 
cell lines such as the promyelocytic leukemia, HL-
60, and the breast cancer, MCF-7. 
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MATERIALS AND METHODS 
 
Cholesteryl butyrate solid lipid nanoparticles 
CBSLN were prepared using the microemulsion 
method reported elsewhere (30, 31). Briefly, CBSLN 
were prepared from cholesteryl butyrate (0.54 mmol) 
(Asia Talent Chemical, Shenzen, China) and 
Epikuron 200 (0.66 mmol) (Cargill, Milan, Italy). 
Epikuron 200 and cholesteryl butyrate were melted 
at 85 °C and a warm solution of sodium glycocholate 
(0.39 mmol) (PCA, Basaluzzo, Italy) was added. 2-
phenylethanol (Sigma Aldrich, Milan, Italy) was 
used as a preservative (0.25% w/v final dispersion). 
The microemulsion was then immediately dispersed 
in cold water (dispersion ratio 1:5 v/v) and washed 
by tangential flow filtration using a Vivaflow50 
membrane (Sartorius Stedim Biotech GmbH, RC, 
Cut-off 100,000 Da) for purification of hydrophilic 
molecules (four washing steps were repeated by 
addition and removal of the same volume of water). 
The aqueous dispersion of CBSLN was then 
sterilized by 0.2 µm filtration before use. Dispersion 
of CBSLN was characterized according to average 
diameter (Zave) and polydispersity index (PI) 
(Photon Correlation Spectroscopy (PCS), Malvern 
Zetasizer - Nano ZS – 176 Deg) and by 
determination of chemical composition (HPLC-UV 
analysis, Agilent 1260 and 1200). The zeta potential 
of the chol-but CBSLN dispersion after final 
sterilizing filtration was also characterized by laser 
Doppler velocimetry (LDV) (Malvern Zetasizer - 
Nano ZS). 
Fluo-cholesteryl butyrate SLN was prepared 
using the warm microemulsion method as for 
unlabeled CBSLN, by simply adding fluorescent dye 
in the lipid phase. Briefly, a warm microemulsion 
was prepared from cholesteryl butyrate (CBSLN 
0.54 mmol), Epikuron 200 (PC) (0.66 mmol), 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiO, λex: 
484 nm / λemiss: 501 nm) (Biotium, Hayward –
USA) ( 0.9 µmol), as the lipid phase and sodium 
glycocholate (NaGC, 0.39 mmol) (PCA, Basaluzzo, 
Italy) in the water phase; 2-phenylethanol (PhOH) 
(Sigma Aldrich, Milan, Italy) was added as a 
preservative (0.25% w/v final dispersion). DiO-
tagged CBSLN aqueous dispersion was washed and 
sterilized as for the previously reported unlabeled 
CBSLN. 
Since the whole lipid matrix of CBSLN 
themselves acts as a prodrug of butyrate, solutions of 
sodium butyrate were freshly prepared in sterile 
water before each experiment and used as a drug 
reference. 
Cell culture and proliferation assay 
HL-60 and MCF-7 cell lines (ICLC, Interlabab Cell 
Line Collection, Genoa, Italy) were cultured in a 
growth medium (RPMI 1640 medium) 
supplemented with 2 mM L-glutamine, 100 UI/mL 
penicillin, 100 µg/mL streptomycin and 10% (v/v) 
heat-inactivated fetal calf serum (Sigma, St Louis, 
MO, USA) in a humidified atmosphere of 5% CO2 
air at 37 °C. 
The effect of butyrate, as NB or CBSLN, on HL-
60 and MCF-7 cell growth was evaluated by WST-1 
cell proliferation assay (Roche Applied Science, 
Penzberg, Germany). 1 × 103 HL-60 and 2.5 × 103 
MCF-7 cells were seeded in 100 μL of growth 
medium in replicates (n = 8) in a 96-well culture 
plate. After 72 h of cell growth, the medium was 
removed and the cells were incubated with the 
experimental medium containing different butyrate 
concentrations (0.01, 0.10, 0.50 and 1.00 mM). At 24 
h and 48 h, WST-1 reagent (10 μL) was added and 
the plates were incubated at 37 °C in 5% CO2 for 2 
h. Well absorbance was measured at 450 nm and 620 
nm (reference wavelength) in the Asys UV 340 
microplate reader (Biochrom, Cambridge, UK). Cell 
proliferation data were expressed as a percentage of 
untreated cells. 
 
Flow cytometry 
Cell death was evaluated using the Dead Cell 
Apoptosis Kit with (allophycocyanin) APC-Annexin 
V and Sytox® Green (Life Technologies, Milan, 
Italy). Briefly, 5 x 105 HL-60 and MCF-7 cells were 
treated with butyrate (NB or CBSLN) 0.50 mM and 
1.00 mM, respectively. The cells were then washed 
twice with 1x annexin-binding buffer at 375 rcf for 5 
min and were stained with APC-Annexin V and 
Sytox® Green at 12, 24 and 48 h. Samples were run 
on the flow cytometer at a 640 nm excitation to 
measure APC-Annexin V (FL4) and at 488 nm to 
measure Sytox® Green (FL1), respectively. Any cell 
debris with low FSC and SSC was excluded from the 
analyses. A total of 10,000 events were analyzed for 
APC-Annexin V (FL4) and Sytox® Green (FL1) 
staining to discriminate apoptotic (Annexin V 
positive) or late apoptotic/necrotic cells (Annexin V 
and Sytox® Green positive) from viable cells 
(Annexin V and Sytox® Green negative). 
Cell cycle distribution was monitored by adding 
2 µM of Vybrant Dye Cycle Green (Invitrogen) live 
cell staining to 106 cells for 30 min at 37 °C. Briefly, 
both the HL-60 and the MCF-7 cell cycle 
distributions were evaluated after the treatment with 
butyrate (NB or CBSLN) 0.50 mM at 12 h and 1.00 
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mM at 48 h, respectively. The samples were run on 
the flow cytometer with a 488 nm excitation to 
measure the Vybrant Dye Cycle Green staining 
(FL2). Flow cytometry was carried out by a C6 flow 
cytometer (Accurri Cytometers, Milan, Italy) and the 
analysis was performed by a FCS Express 4 (BD 
Bioscience, Milan, Italy). 
Cellular uptake studies of CBSLN were carried 
out by flow cytometry with 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiO) used 
as a fluorescence probe. The experiment was 
conducted on 1 × 105 cells in a six-well culture plate. 
Cells were incubated at 37 °C, 5% CO2 in 
supplemented RPMI-1640 medium. Then, HL-60 
and MCF-7 cells were treated with 1 mL of 0.50 mM 
of DiO-tagged CBSLN in RPMI-1640 medium for 1, 
5, 15, 30 and 60 min. After each incubation period, 
the cells were washed three times with PBS, and re-
suspended in 300 µl PBS and run on the flow 
cytometer with a 488 nm excitation to measure the 
DiO staining (FL1). Intracellular fluorescence was 
expressed as the integrated median fluorescence 
intensity (iMFI), which was the product of the 
frequency of DiO-tagged CBSLN positive cells and 
the median fluorescence intensity of the cells. 
Results were expressed as the iMFI ratio, i.e. the 
difference between the iMFI of treated and untreated 
cells and the iMFI of untreated cells (41).  
 
Fluorescence microscopy 
HL-60 and MCF-7 cellular uptake of 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiO)-
tagged CBSLN was investigated by fluorescence 
microscopy. Briefly, the MCF-7 cells were left to 
attach for 24 h on glass coverslips in 24-well plate, 2 
x 105 HL-60 and MCF-7 cells were then incubated 
for 30 min with DiO-tagged CBSLN 0.50 mM. Five 
minutes before the programmed stop time, the cells 
were incubated with 1 µg/mL of 4',6-diamidino-2-
phenylindole (DAPI) for nuclear staining. Once the 
cells had been washed with PBS, the HL-60 cell 
suspensions and the MCF-7 on the coverslip were 
mounted onto a glass slide, observed under a 
DMI4000B fluorescence microscope (Leica, 
Wetzlar, Germany) and photographed. A total of 50 
cells per slide were analyzed at 40x magnification in 
three separate areas, three times in three individual 
experiments. 
 
Real Time RT-PCR 
Depending on the effects obtained on cell growth, 
total RNA was isolated from the HL-60 cells at 6 and 
12 h after NB or CBSLN 0.50 mM treatment and 
from the MCF-7 cells at 24 and 48 h after NB or 
CBSLN 1.00 mM treatment. Briefly, HL-60 and 
MCF-7 cells were collected in an RNA Cell 
Protection Reagent (Qiagen, Milan, Italy) and stored 
at -80 °C. Total RNA was then obtained using the 
RNeasy Plus Mini Kit (Qiagen). The total RNA 
concentration (µg/mL) was determined using the 
Qubit fluorometer (Invitrogen, Milan, Italy) and the 
Quant-IT RNA Assay Kit (Invitrogen) was used. 
Calibration was performed applying a two-point 
standard curve, according to the manufacturer’s 
instructions. The integrity of the RNA samples was 
determined using the total RNA 6000 Nano Kit 
(Agilent Technologies, Milan, Italy) and the Agilent 
2100 Bioanalyzer (Agilent Technologies). 
Real-time RT-PCR analysis was carried out 
using 500 ng of total RNA, which was reverse 
transcribed in a 20 µL cDNA reaction volume using 
the QuantiTect Reverse Transcription Kit (Qiagen). 
In accordance with the manufacturer’s instructions, 
12.5 ng of cDNA was used for each 10 µL real-time 
RT-PCR reaction. Quantitative RT-PCR was 
performed using SsoFast EvaGreen (Bio-Rad, 
Milan, Italy) and the QuantiTect Primer Assay 
(Qiagen) was used as the gene-specific primer pair 
for the panel of genes studied (Table 1). The 
transcript of the reference glyceraldehyde-3-
phosphate dehydrogenase gene (GAPDH) was used 
to normalize mRNA data and real-time PCR was 
performed using a MiniOpticon Real Time PCR 
system (Bio-Rad). The PCR protocol conditions 
were as follows: HotStarTaq DNA polymerase 
activation step at 95 °C for 30 s, followed by 40 
cycles at 95 °C for 5 s and 55 °C for 10 s. All runs 
were performed with at least three independent 
cDNA preparations per sample and all samples were 
run in duplicate. At least two non-template controls 
were included in all PCR runs. The quantification 
data analyses were performed using the Bio-Rad 
CFX Manager Software version 1.6 (Bio-Rad) 
according to the manufacturer’s instructions. These 
analyses were performed in compliance with MIQE 
guidelines (Minimum Information for Publication of 
Quantitative Real-time PCR Experiments) (42). 
 
HD activity quantification 
Depending on the effects on cell growth, the HL-60 
cells were collected at 12 h after NB or CBSLN 0.50 
mM treatment and the MCF-7 cells at 48 h after NB 
or CBSLN 1.00 mM treatment. 
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  Table 1. Gene description 
Gene Primers code Description 
AKT1 QT00085379 Protein kinase B 
APAF1 QT00092358 Apoptotic peptidase activating factor 1 
BAX QT00062090 Pro-apoptosis regulator 
BCL2 QT00031192 Anti-apoptosis regulator 
CDK2 QT00005586 Cyclin-dependent kinase 2  
CDK4  QT00016107 Cyclin-dependent kinase 4 
CDKN1A QT00031192 Cyclin-dependent kinase inhibitor 1A, p21 
CDKN2A QT00089964 Cyclin-dependent kinase inhibitor 2A, p16 
GAPDH  QT01192646 Glyceraldehyde-3-phosphate dehydrogenase  
HDAC1  QT00015239 Histone deacetylase 1 
HDAC2  QT00001890 Histone deacetylase 2 
HDAC4  QT00005810 Histone deacetylase 4 
MAP3K15 QT00041594 Member of the mitogen-activated protein kinase 
NFKB1  QT00063791 Nuclear factor kappa-B DNA binding subunit 
SLC5A8 QT00199367 Sodium-coupled monocarboxylate transporter 1 
SLC16A1 QT00060676 Solute carrier family 16 member 1 
TP53 QT00060235 Tumor suppressor protein, p53 
 
 
In order to evaluate deacetylation by HD enzymes, 
nuclear extracts were prepared using the Nuclear 
Extract Kit (Active Motif, Rixensart, Belgium) to 
obtain the nuclear proteins, starting from 3 x 106 
cells. 
The protein concentration (µg/mL) was 
quantified using the Qubit fluorometer and the 
Quant-IT Protein Assay Kit. Calibration was 
performed applying a two-point standard curve, 
according to the manufacturer’s instructions. We 
then used the colorimetric HD Assay Kit (Active 
Motif) according to the manufacturer’s instructions. 
This colorimetric HD assay uses a short peptide 
substrate containing an acetylated lysine residue that 
can be deacetylated by class I, II and IV HD 
enzymes. Well absorbance was measured at 405 nm 
in the microplate reader Asys UV 340. 
 
p21 protein quantification 
HL-60 cells were collected at 12 h after NB or 
CBSLN 0.50 mM treatment and the MCF-7 cells at 
48 h after NB or CBSLN 1.00 mM treatment. 1 x 106 
cells were washed twice with PBS, collected in PBS 
and stored at -80 °C. The p21 in the cell lysates was 
analyzed using the p21 EIA kit (Enzo Life Sciences, 
Milan, Italy) according to the manufacturer’s 
instructions. The protein concentration (µg/mL) was 
quantified using the Qubit fluorometer and the 
Quant-IT Protein Assay Kit. Calibration was 
performed applying a two-point standard curve, 
according to the manufacturer’s instructions. 
STATISTICAL ANALYSIS 
 
Data are shown as the mean values ± SD of three 
independent experiments. Statistical analyses were 
performed with GraphPad Prism 6.0 software (La 
Jolla, CA, USA) using the analysis of variance (two-
way ANOVA). Bonferroni’s test was used to 
calculate the threshold of significance. Statistical 
significance was set at P < 0.05. 
 
RESULTS 
 
Characterization of cholesteryl butyrate solid 
lipid nanoparticles  
The average diameter (Zave) and polydispersity 
index (PI) of CBSLN after 0.2 µm filtration were 
78.13 nm and 0.240, respectively. The concentration 
of cholesteryl butyrate and consequently of butyrate, 
determined by reversed-phase HPLC after washing 
four times, were 38.6 mM and 38.6 mM, respectively 
and, after 0.2 µm filtration, 36 mM and 36 mM, 
respectively. 
 
Effects of SLN butyrate delivery on cell 
proliferation 
CBSLN were observed to enhance butyrate 
antiproliferative activity in HL-60 cells but not in 
MCF-7 cells, as shown in Figure 1. In HL-60 cells, 
CBSLN determined a significant dose-dependent 
decrease in cell proliferation starting from 24 h of 
exposure, whereas NB induced only a slight 
reduction in cell proliferation at 48 h of exposure to 
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the highest concentration tested (1.00 mM). In MCF-
7 cells, CBSLN did not enhance the cytotoxic effects 
of butyrate, since it determined the same NB activity 
with a significant decrease in cell proliferation 
starting from 24 h of exposure to the highest 
concentration tested (1.00 mM). CBSLN were able 
to increase butyrate activity in leukemic cells but not 
in breast cancer cells, as compared to free butyrate. 
 
Effects of SLN butyrate delivery on cell death 
On the basis of cell proliferation data (Figure 1), HL-
60 cell death was evaluated at 12, 24 and 48 h of 
exposure to 0.50 mM NB or CBSLN. At 0.50 mM, 
CBSLN induced a significant increase in the 
percentage of apoptotic and necrotic cells, which 
reached 50% and 30%, respectively of the whole cell 
population at 12 h. The increase in apoptotic and 
necrotic cell percentage was maintained for up to 48 
h after treatment (Figure 2). Conversely, 0.50 mM 
NB induced an increase in the apoptotic cell 
percentage which reached about 30% of the whole 
cell population only at 48 h (Figure 2). On the basis 
of cell proliferation data, MCF-7 cell death was 
evaluated at 24 and 48 h after 1.00 mM NB or 
CBSLN treatment. A slight increase in the apoptotic 
cell percentage was detectable only at 48 h with NB 
treatment, while the same formulation did not induce 
a significant increase in the percentage of necrotic 
cells (Figure 2). These data demonstrate that CBSLN 
were able to induce a significant increase in 
apoptotic and necrotic cell percentage, compared to 
free butyrate, at 12 h, while CBSLN were not able to 
improve necrotic or apoptotic cell death in MCF-7 
cells. 
 
 
 
  
Figure 1. Effects of SLN butyrate delivery on cell proliferation. HL-60 and MCF-7 cell proliferation after exposure to 
increasing concentrations of butyrate as NB or CBSLN was evaluated at 24 and 48 h by WST-1 assay. Data are expressed as 
a percentage of control cells, i.e. untreated cells (100%). * P < 0.05, ** P < 0.01, *** P < 0.001 statistical significance versus 
control cells; °°° P < 0.001 statistical significance versus NB treated cells.  
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 Figure 2. Effects of SLN butyrate delivery on cell death. Percentages of apoptotic and necrotic cells were obtained by flow 
cytometry with APC-Annexin V and Sytox Green for HL-60 at 12, 24 and 48 h exposure to 0.50 mM NB or CBSLN and for 
MCF-7 at 24 and 48 h exposure to 1.00 mM NB or CBSLN. * P < 0.05, ** P < 0.01, *** P < 0.001 statistical significance 
versus control cells; °° P < 0.01, °°° P < 0.001 statistical significance versus NB treated cells. 
 
Effects of SLN butyrate delivery on cell cycle 
distribution 
The lowest butyrate concentrations able to influence 
cell proliferation, i.e. 0.50 mM for HL-60 cells and 
1.00 mM for MCF-7 cells (Figure 1), were evaluated 
for their effects on cell cycle distribution. Owing to 
the severe decrease in HL-60 cell viability after 0.50 
mM CBSLN treatment, cell cycle distribution was 
only evaluated at 12 h of incubation. A statistically 
significant difference in the percentage of HL-60 
cells in each cell cycle phase was observed after 
exposure to 0.50 mM CBSLN compared to both 
untreated and NB treated cells (Table 2). At 0.50 
mM, CBSLN showed a statistically significant 
increase in HL-60 cells in the G0/G1 phase and a 
reduction in the S and G2/M phases, which was 
compatible with an arrest in the G0/G1 phase (Table 
2). However, little difference was observed, in both 
1.00 mM NB and CBSLN treated cells, in the 
proportion of MCF-7 cells in any cell cycle phase 
(Table 2). Thus, CBSLN were able to increase 
butyrate activity on the leukemic cell cycle, while the 
two butyrate formulations had similar effects on the 
breast cancer cell cycle. 
 
CBSLN cellular uptake 
Since differences in growth, death and cell cycle 
distribution were observed between HL-60 and 
MCF-7 cells exposed to the same CBSLN 
concentrations, their cellular uptake was investigated 
first by means of fluorescence microscopy. Both the 
HL-60 and MCF-7 cells seemed to have internalized 
the DiO-tagged CBSLN 0.50 mM after 30 min of 
incubation in more than 80% of the whole cell 
population (Figure 3a and b).  
In order to explore the DiO-tagged CBSLN 
internalization, a flow cytometric analysis was 
performed. Specifically, leukemia cells were able to 
internalize DiO-tagged CBSLN 0.50 mM with a high 
iMFI ratio 1 min after incubation, reaching 
maximum internalization at 30 min (P < 0.001). The 
MCF-7 DiO-tagged CBSLN uptake was slower and 
almost constant during the time of incubation (Figure 
3c). These data showed that the CBSLN 
internalization rate was higher and the kinetic uptake 
was faster in leukemia cells than in breast cancer 
cells. 
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Table 2. Effects of SLN butyrate delivery on cell cycle distribution 
Butyrate mM HL-60 cells (%) at 12 h exposure 
m
M MCF-7 cells (%) at 48 h exposure 
G0/G1 S G2/M  G0/G1 S G2/M 
                  
Control 0 31.5 ± 2.5 41.6 ± 5.2 26.8 ± 3.1 0 52.5 ± 4.6 37.9 ± 3.2  9.5 ± 1.3 
NB 0.50 34.5 ± 4.1 45.9 ± 4.3 19.4 ± 2.7 1.00 47.3 ± 3.6 32.4 ± 4.5 12.7 ± 3.2 
CBSLN  0.50      85.1 ± 4.2*** 10.8 ± 2.1***     4.3 ± 0.7*** 1.00 51.7 ± 6.4 34.8 ± 5.6 10.7 ± 2.7 
Notes: *** P < 0.001 statistical significance versus control cells 
Effects of SLN butyrate delivery on gene 
expression 
Based on the cell proliferation data (Figure 1), HL-
60 RNA was extracted at 6 and 12 h after 0.50 mM 
NB or CBSLN treatment and MCF-7 RNA was 
extracted at 24 and 48 h after 1.00 mM NB or 
CBSLN treatment. HL-60 samples (n = 18) had an 
RNA integrity number (RIN) of 10.00 ± 0.00 and 
MCF-7 samples (n = 18) had an RIN of 9.95 ± 0.05. 
The fold change in mRNA expression levels of genes 
involved in the butyrate mechanism of action, as 
compared to the control cells, i.e. untreated cells 
(expression level = 1), is reported for HL-60 cells in 
Figure 4 and for MCF-7 cells in Figure 5. 
We analyzed the gene expression profile of HL-
60 at 6 and 12 h after 0.50 mM NB (Figure 4a) or 
CBSLN (Figure 4b) treatment. Of note is that the 
TP53 gene was not expressed in the HL-60 cell line 
(Figure 4a and b). No significant modifications was 
observed in the mRNA expression of the HD genes 
of class I, i.e. HDAC1 and 2 (Figure 4a and b). 
Conversely, the HD gene of class II, HDAC4, was 
significantly over-expressed at 12 h after CBSLN 
treatment (Figure 4b). 
As it is well known that butyrate is able to induce 
cell cycle arrest and apoptosis, we analyzed the 
expression levels of some genes involved in these 
pathways. 
CDK4, which regulates the cell cycle during 
G1/S transition, was slightly over-expressed at 6 h 
after NB (Figure 4a) and 12 h after CBSLN treatment 
(Figure 4b). Furthermore, the mRNA expression 
level of CDKN2A, which codes for the CDK4 
inhibitor p16, was increased at 6 h after NB treatment 
(4.8 ± 0.1, Figure 4a) and, to a greater extent, at 12 h 
after CBSLN treatment (9.8 ± 0.2, Figure 4b). 
CDKN1A, which codes for the CDK inhibitor p21 – 
characterized by a specific sequence on its promoter 
region recognized by butyrate – was significantly 
over-expressed both at 6 and 12 h after NB (Figure 
4a) and CBSLN treatment (Figure 4b). The highest 
mRNA expression level of CDKN1A was observed 
at 12 h after CBSLN treatment (64.00 ± 5.00, Figure  
4b). This expression profile was in line with the 
considerable G0/G1 block and apoptosis observed in 
HL-60 cells after 0.50 mM CBSLN treatment (Table 
2 and Figure 2). As treatment with HDI triggers 
cancer cells in both the extrinsic and intrinsic death 
ligand-induced pathways for apoptosis, we also 
analyzed genes such as AKT1 and APAF1. 
Specifically, it was observed that, AKT1, which is 
involved in the transduction pathway of the tyrosine-
kinase receptor, was significantly over-expressed at 
6 h after NB treatment (Figure 4a) and at 12 h after 
CBSLN treatment (Figure 4b). APAF1, which 
mediates the cytochrome c-dependent autocatalytic 
activation of pro-caspase-9, was significantly over-
expressed at 6 h after NB treatment (Figure 4a) and 
at 12 h after CBSLN treatment (Figure 4b). When the 
pro-apoptotic BAX gene and the anti-apoptotic BCL-
2 gene were taken into consideration, no statistically 
significant differences were observed in the mRNA 
expression levels, either after NB (Figure 4a) or after 
CBSLN (Figure 4b) treatment. Furthermore, the 
expression of MAP3K15 and NFKB1 gene encoding 
transcriptional factors, which play an essential role 
in apoptotic cell death triggered by cellular stresses, 
was affected by neither butyrate, NB (Figure 4a) nor 
CBSLN (Figure 4b) treatment. The expression levels 
of two genes, SLC5A8 and SLC16A1 encoding 
butyrate transporters were also analyzed. There was 
no SLC5A8 expression in HL-60 cells (Figure 6a and 
b), whilst the mRNA expression level of SLC16A1 
remained unaffected by butyrate both as NB (Figure 
6a) and as CBSLN (Figure 6b). 
We analyzed the MCF-7 gene expression profile 
at 24 and 48 h after 1.00 mM NB (Figure 5a) or 
CBSLN (Figure 5b) treatment. Noteworthy is the 
fact that the TP53 gene in the MCF-7 cell line was 
expressed and differentially modulated by NB and 
CBSLN at 24 h, reaching control level at 48 h 
(Figure 5a and b). HDAC1, 2 and 4 were down-
expressed at 24 h and over-expressed at 48 h by NB 
(Figure 5a). Conversely, these genes were over-
expressed at 24 h and down-expressed at 48 h after 
CBSLN treatment (Figure 5b).
J Pharm Pharm Sci (www.cspsCanada.org) 17(2) 231 – 247, 2014 
239 
 Figure 3. CBSLN cellular uptake. Figure a: Representative fluorescence image of HL-60 cells exposed to 0.50 mM 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiO)-tagged cholesteryl butyrate solid lipid nanoparticles (CBSLN) (in green) for 
30 min; DAPI (in blue) was used as nuclear counterstain, at 63x magnification. Figure b: Representative fluorescence image 
of MCF-7 cells exposed to 0.50 mM DiO-tagged CBSLN (in green) for 30 min; DAPI (in blue) was used as nuclear 
counterstain, at 63x magnification. Figure c: Cellular uptake by flow cytometric analysis, cells was exposed to DiO-tagged 
CBSLN for different incubation time (1, 5, 15, 30, 60 min). Fluorescent signal was detected by a flow cytometer with a 488 
nm excitation to measure the DiO staining (FL1) and expressed as integrated median fluorescence intensity (iMFI) ratio 
calculated as reported in Materials and Methods. *** P < 0.001, ****P < 0.0001 statistical significance versus untreated 
cells. 
 
 
mRNA expression levels of CDK2 and CDK4 had 
significantly decreased at 24 h after NB reaching 
control level at 48 h (Figure 5a). CBSLN modulated 
CDK2 expression only at 24 h (Figure 5b). Although 
CDKN2A was down-regulated by both NB and 
CBSLN at 48 h, CBSLN treatment led to an up-
regulation at 24 h (Figure 5a and b). CDKN1A was 
similarly modulated by NB and CBSLN reaching the 
same extent of over-expression at 48 h (Figure 5a 
and b). Moreover, AKT1 was down- regulated at 48 
h by NB and CBSLN treatment, as was NFKB1, 
whilst BAX was slightly over-expressed (Figure 5a 
and b). Regarding the expression of the butyrate 
transporter genes, at 48 h we observed over-
expression of SLC5A8 after NB treatment and over-
expression of SLC16A1 after CBSLN treatment 
(Figure 6c and d). 
 
Effects of SLN butyrate delivery on HD activity 
Data are expressed as the HD activity fold change 
compared to control cells, i.e., untreated cells. HD 
activity was 235.27 ± 36.71 nmol/min/mg in 
untreated HL-60 cells and 192.97 ± 25.42 
nmol/min/mg in untreated MCF-7 cells. 
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 Figure 4. Effects of SLN butyrate delivery on HL-60 mRNA expression. mRNA gene expression was evaluated by real-time 
RT-PCR at 6 and 12 h from treatment with 0.50 mM of butyrate as NB (a) or CBSLN (b). Values are relative to untreated 
cells represented as the dash line, i.e. a value of 1; nd: not detectable; * P < 0.05, ** P < 0.01, *** P < 0.001 statistical 
significance versus untreated cells. 
 
 
There was a significant reduction in total HL-60 HD 
activity after 12 h of exposure to 0.50 mM CBSLN, 
while NB had no effect (Figure 7a). Conversely, 
there was a slight decrease in the HD activity of 
MCF-7 nuclear extract samples after 48 h of 
exposure to 1.00 mM NB, while CBSLN had no 
effect (Figure 7b).  
These alterations in total HD activity are 
consistent with the HDAC4 mRNA over-expression 
observed in HL-60 cells at 12 h of exposure to 0.50 
mM CBSLN (Figure 4b) and in MCF-7 cells at 48 h 
of exposure to 1.00 mM NB (Figure 5a), suggesting 
some kind of compensatory feedback (40). 
 
Effects of SLN butyrate delivery on p21 protein 
expression 
Data are expressed as the p21 protein expression fold 
change compared to control cells, i.e., untreated 
cells. The p21 protein was 2626.67 ± 158.41 pg/mL 
in untreated HL-60 cells and 4760.00 ± 310.03 
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pg/mL in untreated MCF-7 cells. A significant 
increase in p21 protein expression was observed in 
HL-60 cells after 12 h of exposure to 0.50 mM 
CBSLN (Figure 8a), in line with the marked 
CDKN1A mRNA over-expression observed (Figure 
4b). Conversely, there was no difference in the MCF-
7 p21 protein expression as compared to control cells 
after either NB, or CBSLN treatment (Figure 8b). 
This finding is in line with the slight increase in 
CDKN1A mRNA expression observed in MCF-7 
cells after treatment with 1.00 mM NB or after 
CBSLN treatment (Figure 5a and b).
 
 
 
 
 
 Figure 5. Effects of SLN butyrate delivery on MCF-7 mRNA expression. mRNA gene expression was evaluated by real-
time RT-PCR at 24 and 48 h from the treatment with 1.00 mM of butyrate as NB (a) or CBSLN (b). Values are relative to 
untreated cells represented as the dash line, i.e. a value of 1; nd: not detectable; * P < 0.05, ** P < 0.01, *** P < 0.001 
statistical significance versus untreated cells. 
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 Figure 6. Effects of SLN butyrate delivery on mRNA expression of butyrate transporter genes. HL-60 mRNA gene 
expression was evaluated by real-time RT-PCR at 6 and 12 h from the treatment with 0.50 mM of butyrate as NB (a) or 
CBSLN (b). MCF-7 mRNA gene expression was evaluated by real-time RT-PCR at 24 and 48 h from the treatment with 1.00 
mM of butyrate as NB (c) or CBSLN (d). Values are relative to untreated cells represented as the dash line, i.e. a value of 1; 
nd: SLC5A8 gene expression not detectable in HL-60. * P < 0.05, ** P < 0.01, *** P < 0.001 statistical significance versus 
untreated cells. 
 
 
DISCUSSION 
 
Solid lipid nanoparticles are able to improve not only 
the pharmacokinetic, but also the pharmacodynamic 
properties of anti-cancer agents (39, 40, 43-45). 
Butyrate induces apoptosis and blocks in the G0/G1 
phase in most cell lines at concentrations from 2 to 5 
mM (14, 46, 47). Therefore, we investigated how 
solid lipid nanoparticles may influence the butyrate 
anticancer activity at a molecular level. 
CBSLNswere able to improve in vitro butyrate 
anticancer activity at lower concentrations in HL-60,  
but not in MCF-7 cells (Figure 1-2 and Table 2). 
These data are confirmed by the cellular uptake of 
fluorescent CBSLN, which was significantly higher 
in HL-60 than in MCF-7. 
It is reasonable to suppose that the form of 
endocytosis involved in nanoparticle uptake could 
affect both intracellular localization and trafficking 
of the nanoparticles. To the best of our knowledge, 
differences in uptake extent and mechanism by 
hematological and epithelial cancer cell lines have 
not been reported to date. This is in spite of the fact 
that nanoparticles have been shown to exploit more 
than one pathway in their attempt to gain cellular 
entry (45). 
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Figure 7. Effects of SLN butyrate delivery on HD activity. Data are presented as fold change compared to that of control 
cells, i.e. untreated cells. HD activity in untreated HL-60 cells was 235.27 ± 36.71 nmol/min/mg (a) and in untreated MCF-7 
cells 192.97 ± 25.42 nmol/min/mg (b). * P < 0.05, ** P < 0.01 statistical significance versus control cells. 
 
 
 
 
Figure 8. Effects of SLN butyrate delivery on p21 protein expression. Data are presented as fold change compared to that 
of control cells, i.e. untreated cells. p21 in untreated HL-60 cells was 2626.67 ± 158.41 pg/mL (a) and in MCF-7 untreated 
cells 4760.00 ± 310.03 pg/mL (b). ** P < 0.01 statistical significance versus control cells. 
 
 
We hypothesized that the different anticancer 
efficacy of butyrate as CBSLN between HL-60 and 
MCF-7 cells may be due to differences in the 
apoptotic mechanisms involved and/or butyrate 
cellular transport between the two cell lines. First of 
all, we investigated butyrate activity as NB or 
CBSLN in each cell line. 
In HL-60 cells, NB and CBSLN had different 
effects on the expression of genes involved in the 
butyrate mechanism. In particular, NB determined a 
lesser and earlier mRNA over-expression (Figure 4a) 
than CBSLN, which determined a marked over-
expression at 12 h (Figure 4b). A possible 
explanation for this might well be the different cell 
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uptake kinetics as NB or CBSLN, which, in turn, 
leads to a different transcriptional activity. Of note is 
that CBSLN induced an up-regulation of HDAC4 
mRNA expression at 12 h in HL-60 cells (Figure 4b) 
and, at the same time, a significant decrease in total 
HD activity (Figure 7a).  
These data are in line with the hypothesis of a 
HDI-triggered self-regulatory loop due to a 
compensatory feedback pathway of HD transcription 
after inhibition of its enzymatic activity (40). 
Moreover HL-60 cells are TP53 null cells and 
CBSLN induced a marked CDKN1A mRNA over-
expression both at 6 and 12 h (Figure 4b) and a 
significant increase in p21 protein expression at 12 h 
(Figure 8a). In keeping with these data, various 
studies have reported that butyrate dramatically 
increases p21 expression in cancer cells, such as 
osteosarcoma, colon carcinoma, glioma and lung 
cancer (15). The binding of p21 to the cyclin/cyclin-
dependent kinase (CDK) complex is reported to be 
the main mechanism of butyrate induced inhibition 
of proliferation, which plays an essential role in 
G0/G1 arrest. Effectively, it has been reported that 
p21 forms complexes with cyclin D and CDK 4 or 6 
as well as with cyclin E and CDK 2, thus reducing 
CDK activities and leading to inhibition of G1-S 
transition (48). Moreover, CDKN1A coding for p21 
has a specific sequence in its promoter region, which 
is recognized by the Sp1/Sp3 transcription factors. 
Indeed, some authors have reported that the butyrate 
up-regulation of p21 can be explained by selective 
butyrate regulation of the Sp transcriptional 
activators, leading to a common mechanism for cell 
cycle arrest and apoptosis (19, 49).  
Our data are in line with several literature reports 
linking the rise in p21 levels to a histone-direct effect 
of HDI (14, 22, 50). Butyrate may also modulate 
other CDK inhibitors, such as p16 coding by 
CDKN2A, whose transcription is up-regulated by 
CBSLN in HL-60 cells (Figure 4b). This result is in 
line with Siavoshian’s work, where the author 
reported that treatment of HT-29 with butyrate 
strongly induces cyclin D and p21 expression, but 
does not influence CDK4, CDK6 and P16 expression 
(51). The butyrate transporter SLC5A8 was not 
expressed in HL-60 cells (Figure 6a), whereas the 
SLC16A1 transporter was expressed and modulated 
only by CBSLN (Figure 6b). CBSLN was then able 
to enhance the butyrate inhibition of HL-60 cell 
proliferation through a p53 independent pathway as 
a result of HD inhibition, resulting in marked 
CDKN1A mRNA over-expression and an increase in 
p21. Therefore, the different butyrate activity in HL-
60 cells as CBSLN or NB may be related to butyrate 
intracellular trafficking improved by SLN, since the 
active butyrate transporter SLC5A8 was not 
expressed.  
Figure 5 shows the expression profile of genes 
involved in the butyrate mechanism of action in 
MCF-7 cells exposed to NB or CBSLN. Noteworthy 
is the fact that NB and CBSLN determined up-
regulation of the same genes at different time points. 
There was a general up- regulation trend in the same 
genes at 48 h for NB and at 24 h for CBSLN. 
Conversely, NB down-regulated TP53 transcription, 
whilst CBSLN up-regulated it. NB led to a 
significant up-regulation of the mRNA expression of 
HDAC4 at 48 h. These data are in line with the slight 
NB-induced decrease in total HD activity observed 
in the MCF-7 cells (Figure 7b). Some authors have 
reported that butyrate inhibits cell proliferation in 
p53 wild type cancer cells, such as MCF-7, through 
the p53 pathway. Indeed p53 acetylation precedes 
the induction of BAX, suggesting that p53 mediates 
NB-induced apoptosis (52-54). Noteworthy was the 
fact that neither as NB nor as CBSLN was butyrate 
able to up-regulate CDKN1A mRNA expression in 
MCF-7 cells to such an extent as to induce an 
increase in p21 protein expression (Figure 8b). 
Moreover, NB induced a notable up-regulation of the 
mRNA expression of BAX at 48 h. CDK2 and CDK4 
were significantly down-regulated by NB at 24 h, 
reaching control level at 48 h. This result is in line 
with the down-regulation of CDK4 gene expression 
in the human non-small lung carcinoma cell line 
H460 treated with NB (47). Butyrate as NB or 
CBSLN induced a different modulation of the 
butyrate transporters SLC5A8 and SLC16A1 in 
MCF-7 cells (Figure 6c and d), i.e., NB-induced 
SLC5A8 over-expression at 48 h, while CBSLN 
induced SLC16A1 over-expression at the same time 
point. Hence, the same butyrate activity as CBSLN 
or NB in MCF-7 cells may be related to the up-
regulation of the butyrate active transporters genes 
SLC5A8 and SLC16A1.  
Since the primary target of butyrate may be 
transcription in both cell lines, CBSLN determined 
an improved treatment response, as compared to NB, 
only in HL-60 cells due to the cellular survival/death 
network. Such findings were also supported by other 
studies, where low levels of p53 expression are 
linked to a resistance to HDI (55). Although 
butyrate’s ability to stimulate apoptosis in some 
adenocarcinoma cells has been well documented, 
sensitivity to butyrate-induced apoptosis is quite 
variable and some authors have reported that the 
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magnitude of p21 protein induction in colon cancer 
cell lines was smaller in the p53 wild-type cell lines 
than in the p53 mutant cell lines (20). Indeed, using 
a retroviral delivery system, an overexpression of 
p21 in mammary tumor cells led to increased 
apoptosis (55). Furthermore, some data suggest that 
histone hyperacetylation is partly responsible for the 
induction of p21 on colon cancer cell lines, because 
both butyrate and the specific inhibitor of histone 
deacetylase as trichostatin A resulted in a similar 
induction of p21 (56). Moreover, as the ability of 
butyrate to exert its effects depends on its 
intracellular concentration, solid lipid nanoparticles 
may improve butyrate concentration, especially in 
those cells where active butyrate transporters, such 
as SLC5A8, are not expressed (e.g., HL-60 cells). 
Compared to the hydrogen-coupled transporter 
SLC16A1, SLC5A8 appears to have an extremely 
high affinity for butyrate at normal concentrations 
(25). Moreover, this evidence, along with the fact 
that SLC5A8 is coupled to a Na+ concentration 
gradient, means there is a far greater “push” of 
butyrate into the cells than with SLC16A1. Indeed, 
as SLC16A1 relies on an H+ gradient and as the 
magnitude of this gradient across the apical 
membrane is negligible, there is a smaller driving 
force pushing butyrate across (27). Therefore, the 
same effects determined by NB and CBSLN in 
MCF-7 cells may be due to an NB-induced over-
expression of SLC5A8, which may lead to improved 
butyrate cellular uptake. Moreover, SLC5A8 
butyrate-mediated inhibition of HD has been 
reported as the underlying mechanism of the tumor-
suppressive function of SLC5A8 (25). 
 
CONCLUSION 
 
Delivery of butyrate by solid lipid nanoparticles was 
able to considerably improve butyrate transcriptional 
activation in HL-60 cells only, leading to enhanced 
anticancer activity. According to the mRNA gene 
expression profile, we hypothesize that the different 
modulation of gene transcription was due to cell 
properties such as the expression of SLC5A8 with 
different patterns of butyrate internalization as a 
consequence. Indeed, HL-60 does not express 
SLC5A8 (Figure 6a, b), however it was expressed in 
MCF-7 cells (Figure 6c, d). Therefore, on the basis 
of these findings, pharmacological enhancement of 
butyrate transport as solid lipid nanoparticles, 
according to the specific cancer cell properties, may 
well represent a useful therapeutic tool in future 
cancer treatment protocols. 
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